argenx SE (EBR:ARGX)
714.80
+2.40 (0.34%)
Oct 29, 2025, 4:42 PM CET
argenx SE Revenue
argenx SE had revenue of $967.19M USD in the quarter ending June 30, 2025, with 97.62% growth. This brings the company's revenue in the last twelve months to $3.12B, up 88.04% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.22% growth.
Revenue (ttm)
$3.12B
Revenue Growth
+88.04%
P/S Ratio
16.50
Revenue / Employee
$1.95M
Employees
1,599
Market Cap
43.86B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
| Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
| Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
| Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
| Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 6.85B |
| Fagron NV | 918.75M |
| Ion Beam Applications | 585.76M |
| European Medical Solutions | 49.47M |
| Biocartis Group NV | 47.69M |
| Hyloris Pharmaceuticals | 8.46M |
| Nyxoah | 4.93M |
| Onward Medical | 2.72M |
argenx SE News
- 4 hours ago - argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients - GlobeNewsWire
- 2 days ago - Baron Health Care Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha
- 6 days ago - If You Invested $1000 In argenx Stock 5 Years Ago, You Would Have This Much Today - Benzinga
- 12 days ago - argenx Reaches Analyst Target Price - Nasdaq
- 14 days ago - argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session - GlobeNewsWire
- 16 days ago - How Do Investors Really Feel About argenx SE? - Benzinga
- 16 days ago - Wedbush Raises Price Target for ARGX, Maintains Outperform Rating | ARGX Stock News - GuruFocus
- 25 days ago - argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025 - GlobeNewsWire